Praluent Launch Brings Clinical Practice Challenges
Despite enthusiasm about PCSK9 class, the prescribing community will have to wrestle with patient-selection criteria, uncertainty about very low LDL levels and a lack of outcomes data for Sanofi and Regeneron’s alirocumab.
You may also be interested in...
Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.
Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.